S-Amlodipine: An Isomer with Difference - Time to Shift from Racemic Amlodipine

21Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review.

Cite

CITATION STYLE

APA

Dalal, J., Mohan, J. C., Iyengar, S. S., Hiremath, J., Sathyamurthy, I., Bansal, S., … Dasbiswas, A. (2018). S-Amlodipine: An Isomer with Difference - Time to Shift from Racemic Amlodipine. International Journal of Hypertension. Hindawi Limited. https://doi.org/10.1155/2018/8681792

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free